Evidence map›Paper›PMID 34839395›Full record

ArticleCancer causes & control : CCC2022

Kidney cancer trends and risk factors in Lebanon: a 12-year epidemiological study.

Elise Assouad, Said El Hage, Steven Safi, Antonio El Kareh, Elie Mokled, Pascale Salameh

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elise Assouad *Faculty of Medicine, Lebanese American University, Byblos, Lebanon.
Said El Hage *Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon.
Steven SafiFaculty of Medical Sciences, Lebanese University, Hadath, Lebanon. Stevensafi99@gmail.com.ORCID http://orcid.org/0000-0002-7634-8439
Antonio El KarehFaculty of Medical Sciences, Lebanese University, Hadath, Lebanon.
Elie MokledFaculty of Medical Sciences, Lebanese University, Hadath, Lebanon.
Pascale SalamehFaculty of Medical Sciences, Lebanese University, Hadath, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLebanon has witnessed an increase in the rates of several cancer subtypes over the last years. The aim of this study is to examine the incidence rates of kidney cancer in Lebanon over 12 years and to compare them to other countries.

methodsData were collected from the Lebanese National Cancer Registry (NCR) for the time period 2005-2016 (inclusive). Data from other countries were retrieved from an online database "Cancer Incidence in Five Continents." The age specific and age-standardized rates (ASR) were calculated and analyzed using Joinpoint regression.

resultsKidney cancer ranked as the 10th commonest cancer among men and the 19th among women. An age-standardized rate of 3.54 (per 100,000) was obtained. The average ASR was 4.80 for men and 2.27 for women. Kidney cancer showed a significantly rising trend for both genders. Lebanon had the highest ASR for kidney cancer in men and the third highest in women among regional countries.

conclusionLebanon presented an average-to-high ASR for kidney cancer compared to regional countries. However, compared to countries worldwide, Lebanon had a below-average ASR. Nonetheless, with the rising kidney cancer trends, it is important to study the associated risk factors in order to develop proper preventive and screening measures and therefore decrease the incidence rates.

Indexed as

Kidney NeoplasmsEpidemiologic StudiesFemaleHumansIncidenceLebanonMaleRisk FactorsCancerEpidemiologyKidneyLebanonNephrologyOncology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.